^
Association details:
| Biomarker: | CCL5 overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Selzentry (maraviroc) (CCR5 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
Published date:
07/08/2021
Excerpt:
GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC.
Secondary therapy:
temozolomide
DOI:
10.1038/s41422-021-00528-3
